Courtesy of the Brazilian Society of Hemodynamics and Interventional Cardiology (SBHCI).
The SeQuent Please paclitaxel-coated balloon provides non-inferior angiographic results when compared with the Xience everolimus-eluting stent for the treatment of in-stent restenosis.
At 6 months, the minimal lumen diameter was 1.71 mm in the drug-coated balloon arm and 1.74 mm in the Xience arm, a difference that met criteria for non-inferiority (p < 0.0001). There were no differences in clinical endpoints, although the study did not have enough statistical for those endpoints.
Read also: “Fentanyl in Angioplasty: What Is the Price of More Comfort During the Procedure?”
These findings were published simultaneously in the JACC: Cardiovascular Interventions and are concordant with current European guidelines, which provide class IA recommendations for both drug-eluting stents (DES) and drug-coated balloons for the treatment of in-stent restenosis within bare-metal stents (BMS) or DES.
The DARE study was carried out at 8 Dutch centers and enrolled 278 patients with in-stent restenosis (56% had restenosis in a DES). About 60% of patients presented with acute coronary syndrome.
Read also: “MitraClip Procedure Can Be Performed without General Anesthesia”.
DES treatment resulted in a larger minimal lumen diameter and a lower percentage of residual stenosis. Those differences were lost at follow-up by greater late lumen loss in the DES arm (0.45 vs. 0.17 mm; p < 0.001) at the 6-month angiographic follow-up.
Courtesy of the SBHCI.
Original title: A Randomized Comparison of Paclitaxel-Eluting Balloon Versus Everolimus-Eluting Stent for the Treatment of any In-Stent Restenosis: The DARE Trial.
Presenter: José Henriques.
Subscribe to our weekly newsletter
Get the latest scientific articles on interventional cardiology
We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.
